The real-world use of medicines for the management of haematological malignancies in pediatric populations: a scoping review.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
INTRODUCTION: There is limited research on the real-world use of medicines for the management of pediatric cancers, with insufficient understanding of the varied approaches toward treatment across the globe. This scoping review aimed to identify publications focusing on systematic anti-cancer therapy (SACT), along with supplementary medicines, for pediatric patients with hematological malignancies in routine clinical practice globally to provide insights into current practice and identify gaps in the literature. AREAS COVERED: A scoping review methodology, following the Joanna Briggs Institute guidance, was used to identify observational studies, published between January 2013 and February 2023 in PubMed, Embase, and Scopus databases. A total of 82 studies were identified, describing the use of 50 SACT agents and 74 supplementary care medicines. Findings highlighted the implementation of multi-drug therapeutic plans to treat hematological malignancies and the diversity of treatments across settings. Cancer treatment was commonly complemented by the administration of various supplementary medicines. EXPERT OPINION: Further observational studies should be conducted to provide additional insights into pharmacological interventions in under-researched therapeutic areas; in addition, descriptive drug utilization studies would be beneficial from clinical settings where pediatric cancer patients are commonly included in clinical trials to address knowledge gaps on treatments in these settings.